Our current study observed that AFP accurately predicts the development of HBV‐HCC in CHB patients with a diagnostic accuracy that was superior to any single test, including ALT, AST, or NLR, suggesting that AFP still has a relatively high and stable diagnostic value for the HBV‐HCC in the Chinese population. This evidence concerns the gene AFP and hepatocellular carcinoma.